Dolan S, Christofides A, Doucette S, Shafey M
Dalhousie University, St. John, NB.
impact Medicom Inc., Toronto, ON.
Curr Oncol. 2020 Aug;27(4):e420-e432. doi: 10.3747/co.27.7009. Epub 2020 Aug 1.
Because of the global coronavirus pandemic, the 2020 annual scientific meeting of the American Society of Clinical Oncology took place virtually, 29-30 May. At the meeting, results from key studies about the treatment of chronic lymphocytic leukemia (cll) were disseminated. Studies examined the efficacy and safety of ibrutinib, acalabrutinib, zanubrutinib, and venetoclax as monotherapy or in combination with novel agents for patients with treatment-naïve and relapsed or refractory cll. Our meeting report describes the foregoing studies and presents interviews with investigators and commentaries by Canadian hematologists about potential effects on Canadian practice.
由于全球冠状病毒大流行，美国临床肿瘤学会2020年年度科学会议于5月29日至30日以线上形式举行。会议上公布了关于慢性淋巴细胞白血病（CLL）治疗的关键研究结果。这些研究考察了伊布替尼、阿卡替尼、泽布替尼和维奈克拉作为单药治疗或与新型药物联合用于初治、复发或难治性CLL患者的疗效和安全性。我们的会议报告描述了上述研究，并展示了对研究人员的采访以及加拿大血液学家对其对加拿大临床实践潜在影响的评论。
